KDM1A inhibitor doses as low as 0.5 μM could induce FAS expression on tumor cells (Figure S2C), and FAS upregulation by the KDM1A inhibitor remained stable for up to 48 h after inhibitor removal (Figure S2D), allowing subsequent T cell treatment to test combination therapy. The gene discussed is KDM1A; the disease is neoplasm.